Board Member
Zura Bio Ltd (ZURA)Equibles does not estimate personal net worth.
Get an email with a short summary when Vir Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get VIR alertsMark Eisner is recorded as Board Member at Zura Bio Ltd (ZURA). The newest filing on record that lists Mark Eisner as Board Member at Zura Bio Ltd (ZURA) is dated April 30, 2026. Zura Bio Ltd reported in an 8-K filed June 18, 2026 that Mark Eisner was appointed Director, effective June 17, 2026. Zura Bio Ltd reported in an 8-K filed February 23, 2026 that Mark Eisner was appointed director, effective February 21, 2026. Kyntra Bio, Inc. reported in an 8-K filed September 6, 2023 that Mark Eisner resigned as Chief Medical Officer, effective September 8, 2023. The proxy statement of Vir Biotechnology, Inc. reports total compensation of $2,371,484 for Mark Eisner in fiscal 2025, including a base salary of $660,833. Disclosed compensation is on record for 8 fiscal years. Mark Eisner has spoken on 5 earnings calls across 1 company, most recently for Vir Biotechnology, Inc. on February 23, 2026. Vir Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Zura Bio Ltd is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vir Biotechnology, Inc. includes Marianne De Backer, MSc, Ph.D., MBA (CEO and Board Member), Aziz Sawaf (CFO), Brent Sabatini (CFO) and 7 others.
“The Company’s shareholders elected the Director Nominees as directors of the Company, each to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal.”
“On February 21, 2026, the Board appointed each of Dr. Mark Eisner and Dr. Ajay Nirula as directors, effective immediately.”
“I'm pleased to walk you through the latest Phase 1 data for VIR 5500, which have been accepted for an oral presentation at the ASCO GU conference taking place later this week.”
“We've made significant progress across both our infectious disease and oncology portfolios during the second quarter, and I'll walk you through the key developments.”
“I'm pleased to provide an update on our clinical development programs. We've made significant progress across both our infectious disease and oncology portfolios during the first quarter, and I'll walk you through the key developments.”
“We've made significant progress in clinical stage programs, and I'm looking forward to sharing the details with you today. Let's start with our hepatitis delta program, which continues to be a key focus for us.”
“Let's begin with the solstice trial in hepatitis delta. As a reminder, we presented strong preliminary data from our phase two solstice trial in HDV at the EASL Congress in June.”
Source not stated
Start not stated–present
Last confirmed April 30, 2026
Proxy statement
Start not stated–2023-09-08
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vir Biotechnology, Inc. (VIR) | M.D., M.P.H. Executive Vice President and Chief Medical Officer | $660,833 | $2,371,484 |
| 2024 | Vir Biotechnology, Inc. (VIR) | M.D., M.P.H. Executive Vice President and Chief Medical Officer | $379,167 | $2,756,265 |
| 2023 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Former Chief Medical Officer | $650,000 | $3,192,545 |
| 2022 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Former Chief Medical Officer | $630,000 | $4,080,708 |
| 2021 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Former Chief Medical Officer | $600,000 | $3,767,606 |
| 2020 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Chief Medical Officer | $50,000 | $3,917,657 |
| 2019 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Chief Medical Officer | — | — |
| 2018 | Kyntra Bio, Inc. (KYNB) | M.D., M.P.H. Chief Medical Officer | — | — |
